Insider Selling: Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $340,000.00 in Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $850.00, for a total transaction of $340,000.00. Following the sale, the director owned 603 shares of the company’s stock, valued at approximately $512,550. This represents a 39.88% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Kathryn Guarini also recently made the following trade(s):

• On Monday, August 10th, Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock. The shares were sold at an average price of $800.00, for a total value of $320,000.00.

Regeneron Pharmaceuticals Trading Down 1.0%

REGN traded down $8.56 during midday trading on Thursday, reaching $843.47. 496,172 shares of the company’s stock traded hands, compared to its average volume of 839,664. The firm has a fifty day moving average of $729.93 and a two-hundred day moving average of $719.06. The stock has a market capitalization of $86.84 billion, a price-to-earnings ratio of 20.85, a P/E/G ratio of 1.61 and a beta of 0.19. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals, Inc. has a 52 week low of $541.00 and a 52 week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share for the quarter, topping the consensus estimate of $10.16 by $4.13. The business had revenue of $4.29 billion during the quarter, compared to analysts’ expectations of $3.82 billion. Regeneron Pharmaceuticals had a return on equity of 13.47% and a net margin of 27.86%.The business’s revenue was up 16.7% on a year-over-year basis. During the same quarter last year, the business posted $12.81 EPS. On average, equities analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, August 31st. Investors of record on Tuesday, August 18th were issued a $0.94 dividend. The ex-dividend date was Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.4%. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron reported completion of a Phase 1/2 study evaluating its cemiplimab (Libtayo) combination with SNS-101. The update advances a potential oncology program, although no new efficacy results were disclosed. Regeneron’s Cemiplimab Combo Trial With SNS-101 Reaches Completion
• Neutral Sentiment: A market report projects continued growth in the global complement-inhibitors market through 2035 and lists Regeneron among the major industry participants, supporting the company’s longer-term opportunity but offering no company-specific financial update. 2026 Complement Inhibitors Market Analysis Report
• Neutral Sentiment: Analysts remain moderately optimistic about REGN’s outlook, with coverage highlighting its recent outperformance versus the broader healthcare sector. Regeneron Pharmaceuticals Stock: Is REGN Outperforming the Healthcare Sector?
• Negative Sentiment: Multiple law firms are publicizing a securities class action focused on Regeneron’s Phase 3 Fianlimab-Libtayo melanoma trial. The lawsuit alleges that the company’s disclosures about slowing event accrual and the trial protocol understated the risk of failing the primary endpoint; the trial ultimately failed, undermining earlier positive trial-risk messaging. Investors who purchased shares during the alleged class period may seek lead-plaintiff status by September 14, 2026. Hagens Berman Regeneron Securities Fraud Class Action Alert
• Negative Sentiment: The repeated litigation announcements increase headline, financial and reputational risk for Regeneron Pharmaceuticals (REGN). The core concern is that the failed melanoma study could delay or reduce expectations for a key growth opportunity and expose the company to potential damages and legal costs. REGN Investors Securities Fraud Lawsuit Notice

Analyst Upgrades and Downgrades

REGN has been the subject of several research reports. Weiss Ratings restated a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a report on Wednesday, June 24th. Leerink Partners raised their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the stock a “market perform” rating in a report on Monday, August 17th. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective on the stock in a research report on Tuesday, July 7th. Citigroup upped their target price on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a report on Monday, August 3rd. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $730.00 to $758.00 and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Fourteen research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $800.36.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of REGN. Brighton Jones LLC grew its holdings in Regeneron Pharmaceuticals by 261.8% in the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares during the period. Dynamic Technology Lab Private Ltd purchased a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $226,000. Arrowstreet Capital Limited Partnership purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $3,183,000. Gabelli Funds LLC boosted its position in shares of Regeneron Pharmaceuticals by 3.0% in the 2nd quarter. Gabelli Funds LLC now owns 1,863 shares of the biopharmaceutical company’s stock worth $978,000 after purchasing an additional 55 shares in the last quarter. Finally, Sei Investments Co. boosted its position in shares of Regeneron Pharmaceuticals by 18.8% in the 2nd quarter. Sei Investments Co. now owns 32,341 shares of the biopharmaceutical company’s stock worth $16,985,000 after purchasing an additional 5,120 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.